Optics, Machine Vision Algorithms at Heart of Epic-USC Collaboration
Epic Sciences Inc., a diagnostics and disease profiling company, announced it has entered into an exclusive license and collaboration agreement with the University of Southern California (USC) Michelson Center for Convergent Bioscience, and the center’s Dr. Peter Kuhn, who leads USC’s Convergent Science Institute in Cancer (CSI-Cancer). The collaboration enhances the ability to provide precision characterizations of rare circulating tumor cells (CTCs). Epic is currently developing CTCs into liquid biopsy diagnostics for characterizing cancers to better guide treatment decisions.
Epic’s platform uses precision optics paired with AI-trained machine vision algorithms to analyze fluorescent antibodies-treated blood. System sensitivity is sufficient to detect a single rare cell in 10 million nucleated cells.
Through the newly formed agreement, USC Michelson will provide Epic access to comprehensive liquid biopsy from Kuhn’s laboratory. That access will help expand the company’s platform to provide in-depth characterization of both the cell-free fractions and CTCs in the liquid biopsy, using genomic, proteomic, and AI-based morphological tools acquired from a single blood draw.
LATEST NEWS
- LED Display Guides Surgery with Real-Time Visuals of Brain Activity
May 16, 2024
- George Mason University Receives Air Force Funding for Imaging, Digital Twins Lab
May 16, 2024
- Intel Appoints Vice President, General Manager of Foundry Arm: People in the News: 5/15/24
May 15, 2024
- Agreements Fortify NVIDIA's Role as Global Partner in Quantum Supercomputing
May 15, 2024
- Compact Single-Photon Lidar Provides High Resolution for Air and Space
May 14, 2024
- Lightium Receives $2.9M to Commercialize Data Center Tech
May 14, 2024
- Laser-Treated Cork Remedies Oil Spills Sustainably with Solar
May 13, 2024
- Optofluidic Antenna Enhances Single-Molecule Sensitivity in Liquid
May 13, 2024